Moderna’s COVID-19 vaccine OK’d in Canada for children aged 6 months and older

0
15

Moderna Inc. MRNA, -6.61% said Thursday its COVID-19 vaccine Spikevax was approved by Health Canada for use in children aged six months to five years. The biotechnology company said the two-dose regimen for children in that age group is completed in one month, the same as for adults, adolescents and children over five years old. Moderna’s vaccine was authorized in the U.S. last month for use in that age group. Moderna’s stock, which slumped 5.1% in midday trading, has slipped 1.8% over the past three months, while the iShares Biotechnology ETF IBB, -1.68% has lost 7.1% and the S&P 500 SPX, -0.30% has dropped 14.3%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleCommodities Corner: Why Biden’s visit to Saudi Arabia is unlikely to contribute much to oil’s price decline
Next articlePinterest stock jumps 20% after hours on report of Elliott Management stake

LEAVE A REPLY

Please enter your comment!
Please enter your name here